Moleculon Inc said itsuccessfully completed initial tests in animals of itsPoroplastic transdermal nicotine delivery system to helpsmokers break the habit.    Transdermal systems are designed to deliver drugs throughthe skin in constant dosages.    The company said it is discussing licensing and marketingagreements for the product with a major internationalpharmaceutical firm, but did not identify the firm. It alsosaid it retained Allen and Company, New York, as its financialadvisor. Reuter&#3;